Evidence map›Paper›PMID 42316179›Full record

ReviewJournal of translational medicine2026

Computational prediction of TCR cross-reactivity: principles, challenges and translational opportunities.

Wenzhen Li, Yu Pan, Xu Wu, Yuting Song, Yin Wang, Lu Xie

Abstract readReview
In one paragraph

Review in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Wenzhen Li *Shanghai-MOST Key Laboratory of Health and Disease Genomics, Shanghai Institute for Biomedical and Pharmaceutical Technologies, Fudan University, Shanghai, China.
Yu Pan *School of Intelligent Medicine, China Medical University, Liaoning, 110122, P.R. China.
Xu WuDepartment of Histoembryology, Genetics and Developmental Biology, Shanghai Key Laboratory of Reproductive Medicine, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
Yuting SongSchool of Intelligent Medicine, China Medical University, Liaoning, 110122, P.R. China.
Yin WangSchool of Intelligent Medicine, China Medical University, Liaoning, 110122, P.R. China.
Lu XieShanghai-MOST Key Laboratory of Health and Disease Genomics, Shanghai Institute for Biomedical and Pharmaceutical Technologies, Fudan University, Shanghai, China. xielu@sibpt.cn.ORCID 0000-0001-7541-2243

Funding

National Natural Science Foundation of China No.31870829Shanghai Municipal Health Commission Collaborative Innovation Cluster Project 2019CXJQ02STCSM No. 24JS2840300; 25JS2850400
6 · The paper itself

Abstract

T-cell receptor (TCR) cross-reactivity, whereby a single TCR recognizes multiple peptide-MHC (pMHC) ligands, is essential for immune surveillance but also represents a major safety challenge for TCR-based therapeutics because of severe off-target toxicities. Rapid advances in immune-repertoire sequencing, structural biology, and immunopeptidomics have accelerated computational efforts to characterize cross-reactive recognition at scale. However, most existing methods are adapted from conventional TCR-pMHC specificity prediction and remain insufficiently aligned with the one-to-many, structurally plastic, and context-dependent nature of cross-reactivity. Here, we review the main data resources supporting TCR cross-reactivity modeling, including sequence- and structure-centric databases, and highlight persistent limitations, such as scarce explicitly annotated cross-reactive TCRs, strong biases toward viral epitopes and common HLA alleles, limited paired αβ-chain information, and a lack of rigorously validated negative examples. We then compare the major computational paradigms-sequence-based, structure-based, machine-learning, and multimodal approaches-with emphasis on their respective strengths and limitations in interpretability, generalization, and scalability. Finally, we discuss emerging translational applications and outline key priorities for the field, including dedicated datasets, rigorous benchmarking, and biologically grounded multimodal models to enable safer and more clinically actionable TCR-based immunotherapies.

Indexed as

Computational BiologyReceptors, Antigen, T-CellTranslational Research, BiomedicalAnimalsCross ReactionsHumansImmunoinformaticsReceptors, Antigen, T-Cell

Identifiers

PMID42316179
PMCPMC13527922

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.